Jci_page_head_homepage_01 Jci_page_head_homepage_02
George C. Tsokos, Maria Tsokos
Published in Volume 112, Issue 9
J Clin Invest. 2003; 112(9):1315–1317 doi:10.1172/JCI20297
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 1

Gene-modified cell therapy in arthritis. (a) DCs prepared from either the peripheral blood or the bone marrow are pulsed with collagen type II (CII) and transfected with an adenovirus expressing TRAIL (AdTRAIL) to produce CII-DC-AdTRAIL-DOX. (b) Injection of CII into mice leads to a cascade of events that include lymphocyte activation, lymphokine production followed by synovial cell proliferation, and joint inflammation. (c) Infusion of DOX-inducible TRAIL-expressing DCs pulsed with CII suppresses collagen-induced arthritis (CIA) by eliminating CII-specific T cells.